Germany
Resolve Biosciences, known as "The Pioneers in Molecular Cartography," is at the forefront of biotechnology innovation. Founded in 2020 and headquartered in Germany, the company leverages its proprietary Molecular Cartography™ platform to provide scientists with unprecedented resolution in single-cell spatial biology.
The platform's advanced multiplexed single-molecule detection technology allows for full spatial context at subcellular levels, enhancing research in oncology, neuroscience, and infectious disease by enabling the identification of individual transcripts and rare signals. This groundbreaking technology has been in development since 2016 and is now available through an oversubscribed early access program.
In their latest funding round, Resolve Biosciences secured a $71.00M Series B investment in October 2022, with contributions from investors including EDBI, NRW BANK, Patient Square Capital, Alafi Capital, and PS Capital Partners, underscoring strong industry confidence in the company's potential and growth trajectory.
